JAMA. 2024;332(15):1228. doi:10.1001/jama.2024.19127 Full Text To more closely target SARS-CoV-2 variants currently circulating in the US, the US Food and Drug Administration (FDA) authorized an updated formula of the messenger RNA (mRNA) COVID-19 vaccine, the agency announced...
In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged =18 years with immunocompromising conditions, ...
Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has not been approved or licensed by the FDA but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and...
The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) was issued to Pfizer. The approval of Spikevax (COVID-19 Vaccine, mRNA) (2024-2025 Formula) ...
(Reuters) -The U.S. Centers for Disease Control and Prevention has recommended that individuals aged six months and older should be given an updated COVID-19 vaccine for the 2024-25 immunization campaign, irrespective of whether they have previously been vaccinated for the...
"Receiving an updated 2024-2025 COVID-19 vaccine can restore and enhance protection against the virus variants currently responsible for most infections and hospitalizations in the United States. COVID-19 vaccination also reduces the chance of suffering the effects of Long COVID, which can develop ...
Approval of Spikevax (COVID-19 Vaccine, mRNA) to include the 2023-2024 formula, a change to a single dose for individuals 18 years of age and older, and approval of a single dose for individuals 12 through 17 years of age. Spikevax was previously ...
“Barring the emergence of a markedly more virulent variant, the FDA anticipates that the composition of Covid-19 vaccines may need to be updated annually, as is done for the seasonal influenza vaccine,” the agency said. Consumer / Employer ...
In a unanimous 11-0 vote, the ACIP recommend that everyone 6 months of age and older should receive an updated COVID-19 vaccine, similar to last year's recommendation. The committee also voted unanimously that everyone 6 months of age and older should receive an updated 2024-2025 influenza ...
Novavax NVAX filed a regulatory application to the EMA, which seeks to update its protein-based COVID-19 vaccine for the 2024/2025 vaccination campaign.